Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6751–6800 of 18650
former Interim Chief Financial Officer, Fatima Dhalla, has resigned as the Interim Chief Financial Officer of the Company , effective January 19, 2024.
On January 24, 2024, the Board of Directors of Splash Beverage Group, Inc. (the “Company”) appointed Ms. Stacy McLaughlin to serve as Chief Financial Officer of the Company, effective as of the same date.
On January 29, 2024, the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.
On January 29, 2024, Nick Leschly informed the Company of his resignation as the Company’s president and chief executive officer effective upon the date of the Closing.
On January 29, 2024, the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.
on January 22, 2024, the Company and Eric T. Kalamaras, the former Chief Financial Officer of the Company, agreed that Mr. Kalamaras’s employment would cease effective as of January 22, 2024.
On January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s Chief Financial Officer.
the Board appointed Kevin Rubin, age 49, and the Company's existing Chief Financial Officer, to become the Company's interim CEO, effective as of the Resignation Date.
Mark Anderson, the Chief Executive Officer ("CEO") and a member of the Board of Directors (the "Board") of Alteryx, Inc. (the "Company"), resigned from his role as CEO and as a member of the Board, effective January 26, 2024
On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).
Appointment of Interim Chief Executive Officer On January 28, 2024, the Board appointed Glen D. Weinstein as the Company’s Interim Chief Executive Officer.
On January 28, 2024, Colin Angle stepped down as Chief Executive Officer and chairman of the Board of Directors of the Company (“Board”).
Effective February 1, 2024, Mr. Smith will return from his medical leave and resume his duties and responsibilities as CEO of the Company.
On the Effective Date, the Company appointed Mr. Ault as its Chairman of the Board as well as its Chief Executive Officer.
and (ii) Jay Puchir, its former Chief Financial Officer
the Company, accepted the resignations of (i) Randy May, its former Chairman of the Board of Directors (the “ Board ”) in such capacity, and as the Company’s Chief Executive Officer
On January 28, 2024, the board of directors (the “Board”) of Rocky Mountain Chocolate Factory (the “Company”) appointed Starlette B. Johnson to the position of Interim Chief Executive Officer, effective immediately.
On January 27, 2024, Robert Sarlls’ employment as Chief Executive Officer of the Company was terminated without Cause (as such term is defined in Mr. Sarlls’ offer letter with the Company, dated May 3, 2022, the “Sarlls Offer Letter”), effective immediately.
On January 25, 2024, the Company appointed Jennifer L. Callahan as the Company’s Senior Vice President and Chief Financial Officer, effective immediately.
On January 26, 2024, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s Chief Executive Officer and will serve as its principal executive officer, effective as of January 26, 2024.
On January 10, 2024, the Company entered into an agreement with Rapid Deployment LLC d/b/a InterimExecs (“InterimExecs”), under which Mitchell Cohen will serve as the Company’s Interim CFO, effective February 1, 2024.
On January 23, 2024, Antonio Migliarese informed the Company that he would be resigning from his position as CFO, effective January 31, 2024.
On January 29, 2024, the Company appointed Yolanda Goodell to be the Interim Chief Executive Officer and the Principal Executive Officer.
On January 23, 2024, the Company accepted the letter of resignation of Jose Maria Eduardo Gonzalez Romero as a director of the Company and from all executive offices he held, including: Chief Executive Officer; Chief Financial Officer, President and Secretary, effective January 29, 2024.
On January 29, 2024, the Company appointed Francis Pittilloni to be the Interim Chief Financial Officer, Principal Financial Officer and Chief Operations Officer.
On January 29, 2024, Daniel Puckett resigned as Chief Financial Officer of the Company, effective as of the Effective Date.
On January 28, 2024, the board of directors of Shockwave Medical, Inc. (the “Company”) appointed Renee Gaeta as Chief Financial Officer and to act as the Company’s principal financial officer for Securities and Exchange Commission (“SEC”) reporting purposes, effective as of February 5, 2024 (the “Effective Date”).
On December 27, 2023, the Board appointed Colin Ellis as Chief Financial Officer of the Company.
On December 27, 2023, the Board of Directors (the “Board”) of Fintech Scion Limited (the “Company”) accepted the resignation of Shalom Dodoun, the Chief Executive Officer of the Company, effective immediately (the “Separation Date”).
Effective January 16, 2024, Frank Chessman resigned as the President and Chief Executive Officer of our company.
On the same date, we appointed David Guarino as our Interim Chief Executive Officer and President.
Mr. Olafsson had previously provided written notice of his intention to resign as an employee effective January 29, 2024.
As previously disclosed, Mr. Garutti has informed the Company’s Board of Directors that he will retire from the Company in 2024 as its Chief Executive Officer and as an executive Board member upon the selection of his successor, but that he will serve as an advisor following this time through the end of 2024 to ensure a proper transition.
On January 24, 2024, Daniel Menold ceased to be the principal accounting officer of CymaBay and Harish Shantharam became the principal accounting officer in addition to his role as principal financial officer and Chief Financial Officer.
Effective January 25, 2024, the Board appointed Kostas Dafoulas to serve as the Company’s interim Chief Financial Officer following the retirement of Mr. James.
Effective January 25, 2024, Michael James retired from his positions as Chief Financial Officer, Treasurer, Secretary and Director of the Company.
On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.
Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer
On the same day, the Board of Directors appointed Wei Fang to serve as the Registrant’s Chief Financial Officer.
On January 23, 2024 Shufang Gao resigned from his position as the Registrant’s Chief Financial Officer.
The executive officers of Merger Sub immediately prior to the Effective Time were Ryan Fukushima, serving as Chief Executive Officer, and Zack Malkin, serving as Chief Financial Officer and Secretary.
The executive officers of Merger Sub immediately prior to the Effective Time were Ryan Fukushima, serving as Chief Executive Officer, and Zack Malkin, serving as Chief Financial Officer and Secretary.
On January 25 , 2024, Analog Devices, Inc. (the “Company”) announced the appointment of Richard C. Puccio, Jr. as Executive Vice President and Chief Financial Officer (principal financial officer), effective as of February 5, 2024.
On January 23, 2024, upon Mr. Martin’s appointment as the Company’s Chief Financial Officer, Kenneth S. Booth, the Company’s Chief Executive Officer, ceased to serve as the Company’s principal financial officer.
On January 23, 2024, effective on such date, the board of directors (the “Board”) of Credit Acceptance Corporation (referred to as the “Company,” “Credit Acceptance,” “we,” “our” or “us”) appointed Jay D. Martin, who had been serving as our Senior Vice President, Finance and Accounting and, as such, our principal accounting officer, as the Company’s Chief Financial Officer.
on January 22, 2024, the Board appointed Mr. Sasson to act as the principal financial officer of the Company for SEC reporting purposes, and he will serve in such role until a new principal financial officer is appointed by the Company.
On January 19, 2024, Mustang Bio, Inc. (the “Company”) appointed James Murphy as the Company’s Interim Chief Financial Officer.
Effective January 29, 2024, Eddie Ni, who currently serves as Chief Executive Officer of the Registrant and a member of the Board of Directors, was appointed to serve as Chief Financial Officer as well.
On January 24, 2024, Ray Chen, Chief Financial Officer of Goldenstone Acquisition Limited (the “Registrant”) resigned his position as Chief Financial Officer with such resignation to be effective as of January 29, 2024.
On January 19, 2024, the Board of Directors (the “Board”) of the Company appointed Teresa Gallo as the Chief Executive Officer (the “CEO”) of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.